文献速递核素与放射性配体治疗神经核医学

PARP-1靶向放疗在小鼠胶质母细胞瘤模型中的研究

PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
PubMed 文献 · J Nucl Med · 2018-03-23

研究合成131I标记的PARP-1治疗药物131I-PARPi,在体外和体内评估其药理学特性。皮下模型中治疗组小鼠生存期显著长于赋形剂组(29 vs 22天,P<0.005);原位模型中增强对流交付可有效滞留于肿瘤而快速清除于健康脑组织。

要点

  • 131I-PARPi在皮下胶质母细胞瘤模型中使小鼠生存期显著长于赋形剂组(29 vs 22天,P<0.005)。
  • 131I-PARPi瘤内注射活性递送剂量为134.1 cGy/MBq,肝、肾等非靶组织剂量显著更低。
  • 增强对流交付在原位脑肿瘤中有效滞留131I-PARPi,同时从健康脑组织快速清除。

核心结论

  • 结果表明131I-PARPi作为治疗药物具有高度潜力,并凸显PARP作为放射性核素治疗靶点的相关性。
  • 放射治疗在脑肿瘤治疗中发挥不可或缺的作用,放射性标记的PARP治疗药物最终可能改善标准治疗。

研究设计与样本

  • 研究合成131I标记的PARP-1治疗药物,并在体外和体内研究其药理学。
  • 采用皮下肿瘤模型量化滞留时间和治疗效果。
  • 采用原位胶质母细胞瘤模型联合植入式渗透泵系统模拟瘤内增强对流交付,研究131I-PARPi的局部给药。

主要发现

  • 131I-PARPi是一种1(2H)-酞嗪酮,结构与FDA批准的PARP抑制剂AZD-2281相似。
  • 体外研究显示131I-PARPi与AZD-2281具有相似的药理学特征。
  • 131I-PARPi瘤内注射活性递送剂量为134.1 cGy/MBq,包括肝和肾在内的非靶组织剂量显著更低。
  • 转染p53生物发光报告基因的U87-MG细胞中p53激活显示治疗肿瘤的辐射损伤和细胞死亡。
  • 皮下模型中,治疗组小鼠生存期显著长于赋形剂组(29 vs 22天,P<0.005);增强对流交付在原位脑肿瘤中有效滞留131I-PARPi,同时从健康脑组织快速清除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) is overexpressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific small molecule inhibitors, PARP-1 is a near-ideal target to develop novel radiotherapeutics to induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. Methods: We synthesized an 131I-labeled PARP-1 therapeutic and investigated its pharmacology in vitro and in vivo. A subcutaneous tumor model was used to quantify retention times and therapeutic efficacy. A potential clinical scenario, intratumoral convection-enhanced delivery, was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of 131I-PARPi (PARPi is PARP inhibitor). Results:131I-PARPi is a 1(2H)-phthalazinone, similar in structure to the Food and Drug Administration-approved PARP inhibitor AZD-2281. In vitro studies have shown that 131I-PARPi and AZD-2281 share similar pharmacologic profiles. 131I-PARPi delivered 134.1 cGy/MBq intratumoral injected activity. Doses to nontarget tissues, including liver and kidney, were significantly lower. Radiation damage and cell death in treated tumors were shown by p53 activation in U87-MG cells transfected with a p53-bioluminescent reporter. Treated mice showed significantly longer survival than mice receiving vehicle (29 vs. 22 d, P < 0.005) in a subcutaneous model. Convection-enhanced delivery demonstrated efficient retention of 131I-PARPi in orthotopic brain tumors, while quickly clearing from healthy brain tissue. Conclusion: Our results demonstrate 131I-PARPi's high potential as a therapeutic and highlight PARP's relevance as a target for radionuclide therapy. Radiation plays an integral role in brain tumor therapy, and radiolabeled PARP therapeutics could ultimately lead to improvements in the standard of care.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jannetti SA, Carlucci G, Carney B, et al. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. J Nucl Med. 2018. PMID: 29572254. doi:10.2967/jnumed.117.205054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。